XOMA Royalty Corp. (XOMA)
Oxford Ledge is still expanding full research coverage of XOMA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
XOMA funds biotech drug development by acquiring rights to future milestone and royalty payments, operating a diversified portfolio of over 120 assets.
SEC filings
- 8-K Termination of material agreement; Completion of acquisition or disposition; Delisting / transfer of listing; 3.03; 5.01; Departure/election of directors or officers; Shareholder vote results; Other material event; Financial statements and exhibits 2026-07-14
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-12
- 8-K Departure/election of directors or officers; Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-05-22
- 8-K Entry into material agreement; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-12
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for XOMA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open XOMA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.